INmune Bio partners with Quantum Computing Inc. to apply quantum optimization, AI in Alzheimer’s drug research

• INmune Bio entered a collaboration with Quantum Computing to apply quantum computing, AI, and analytics to expand research on XPro1595.
• Work will use QCi’s Dirac-3S quantum optimization machine with clinical and public datasets to identify new indications and biomarkers.
• Partnership targets diseases with biology aligned to XPro’s selective inhibition of soluble TNF, aiming to prioritize candidates with higher success odds.
• Stage 1 marks QCi’s first commercial pharma and biotech customer, with options for additional work as programs advance.
• Teams will benchmark quantum optimization results against conventional statistical and machine-learning methods to assess where quantum adds value.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610140845PRIMZONEFULLFEED9845312) on October 14, 2026, and is solely responsible for the information contained therein.